J Clin Pharm Ther. 2016 Jun;41(3):351-353. doi: 10.1111/jcpt.12359. Epub 2016 Feb 06.
'On-demand' romiplostim therapy in immune thrombocytopenia.
Journal of clinical pharmacy and therapeutics
M Mitrovic, I Elezovic, N Suvajdzic-Vukovic
Affiliations
Affiliations
- Clinic of Haematology, Clinical Centre of Serbia, Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
PMID: 26849975
DOI: 10.1111/jcpt.12359
Abstract
WHAT IS KNOWN AND OBJECTIVE: Although thrombopoietin receptor agonists are a second-line treatment for refractory immune thrombocytopenia (ITP), we lack guidelines recommending maintenance modality in patients who achieve complete remission (CR).
CASE SUMMARY: We report a patient with refractory ITP who achieved CR on romiplostim. Obtaining romiplostim for 6 months of therapy, we decided to try extending this by modifying the standard treatment regimen. Romiplostim was successfully administered 'on-demand', only if the patient's platelet count dropped below 150 × 10
WHAT IS NEW AND CONCLUSION: The strategy of 'on-demand' therapy is a promising procedure for the maintenance of response, lowering costs and improving treatment safety.
© 2016 John Wiley & Sons Ltd.
Keywords: immune thrombocytopenia; thrombopoietin receptor agonists; ‘on-demand’ therapy
Publication Types
